ALTUVIIIO phase 3 data on bleed protection in children with hemophilia A
Lynn Malec, MD, joined us to discuss the phase 3 XTEND-Kids study of ALTUVIIIO in pediatric patients with hemophilia A.
On May 10, 2024, the FDA approved an updated label for ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] (Sanofi), with data demonstrating that once-weekly dosing provides bleed protection in children with hemophilia A.1
Lynn Malec, MD, medical director, Comprehensive Center for Bleeding Disorder; associate investigator, The Versiti Blood Research Institute; and associate professor of Medicine and Pediatrics, The Medical College of Wisconsin, joined Contemporary Pediatrics to discuss the data from the phase 3 XTEND-Kids study (NCT04759131).1
"This was a medicine that was approved for prevention of bleeds in hemophilia A [patients] using just once-weekly dosing, which is quite a change for the way patients are able to be treated in the hemophilia community," Malec said. "The XTEND-Kids study was a pediatric study alone. Patients [who] were eligible for this study are patients with severe hemophilia A that had previously been treated with a factor 8 product."
ALTUVIIIO provided high-sustained factor levels with once-weekly dosing in children under 12 with hemophilia A, with XTEND-Kids results demonstrating highly effective bleed protection in hemophilia A with no inhibitor development to factor VIII, according to Sanofi.2
"What we saw in the XTEND-Kids study was that thankfully none of the patients developed inhibitors, so none of them developed an immune reaction to the factor 8 medicine that would make it ineffective," Malec said. "More importantly for me as a treater, as a safety signal we saw that there was really excellent bleed control for patients in the study."
References:
1. Fitch J. FDA approves ALTUVIIIO updated label for bleed protection in children with hemophilia. Contemporary Pediatrics. May 13, 2024. Accessed August 12, 2024. https://www.contemporarypediatrics.com/view/fda-approves-altuviiio-updated-label-for-bleed-protection-in-children-with-hemophilia-a
2. Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A. Sanofi. Press release. July 17, 2024. Accessed August 12, 2024.
Lawrence Eichenfield, MD, talks tapinarof cream, 1%, nemolizumab FDA approvals for atopic dermatitis
December 20th 2024"Tapinarof comes in with that mixture of the short-term studies and longer-term studies intermittently, giving us a nice, effective alternative non-steroid for eczema across the ages."
